BHVN Biohaven Pharmaceutical Holding Co Ltd

USD 38.09 0.00 0
Icon

Biohaven Pharmaceutical Holding Co Ltd (BHVN) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NYE
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 38.09

0.00 (0.00)%

USD 3.36B

0.98M

USD 59.77(+56.92%)

USD 12.33 (-67.63%)

Icon

BHVN

Biohaven Pharmaceutical Holding Co Ltd (USD)
COMMON STOCK | NYE
USD 38.09
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 3.36B

USD 12.33 (-67.63%)

USD 38.09

Biohaven Pharmaceutical Holding Co Ltd (BHVN) Stock Forecast

Show ratings and price targets of :
USD 59.77
(+56.92%)

Based on the Biohaven Pharmaceutical Holding Co Ltd stock forecast from 6 analysts, the average analyst target price for Biohaven Pharmaceutical Holding Co Ltd is USD 59.77 over the next 12 months. Biohaven Pharmaceutical Holding Co Ltd’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Biohaven Pharmaceutical Holding Co Ltd is Slightly Bearish, which is based on 2 positive signals and 4 negative signals. At the last closing, Biohaven Pharmaceutical Holding Co Ltd’s stock price was USD 38.09. Biohaven Pharmaceutical Holding Co Ltd’s stock price has changed by +11.80% over the past week, +14.01% over the past month and +55.47% over the last year.

No recent analyst target price found for Biohaven Pharmaceutical Holding Co Ltd
No recent average analyst rating found for Biohaven Pharmaceutical Holding Co Ltd

Company Overview Biohaven Pharmaceutical Holding Co Ltd

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neur...Read More

https://www.biohaven.com

215 Church Street, New Haven, CT, United States, 06510

239

December

USD

USA

Adjusted Closing Price for Biohaven Pharmaceutical Holding Co Ltd (BHVN)

Loading...

Unadjusted Closing Price for Biohaven Pharmaceutical Holding Co Ltd (BHVN)

Loading...

Share Trading Volume for Biohaven Pharmaceutical Holding Co Ltd Shares

Loading...

Compare Performance of Biohaven Pharmaceutical Holding Co Ltd Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for BHVN

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Biohaven Pharmaceutical Holding Co Ltd (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NVO
Novo Nordisk A/S 0.00 (0.00%) USD634.05B 49.43 4.92

ETFs Containing BHVN

Symbol Name BHVN's Weight Expense Ratio Price(Change) Market Cap
IBRN
iShares Trust - iShares N.. 4.12 % 0.47 % 0.00 (0.00%) USD3.84M

Frequently Asked Questions About Biohaven Pharmaceutical Holding Co Ltd (BHVN) Stock

Based on ratings from 6 analysts Biohaven Pharmaceutical Holding Co Ltd's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 13 buy, sell and hold ratings.

Unfortunately we do not have enough data on BHVN's stock to indicate if its a good dividend stock.

Based on targets from 6 analysts, the average taret price for BHVN is USD 59.77 over the next 12 months. The maximum analyst target price is USD 66 while the minimum anlayst target price is USD 55.

Unfortunately we do not have enough data on BHVN's stock to indicate if its overvalued.

The last closing price of BHVN's stock was USD 38.09.

The most recent market capitalization for BHVN is USD 3.36B.

Based on targets from 6 analysts, the average taret price for BHVN is projected at USD 59.77 over the next 12 months. This means that BHVN's stock price may go up by +56.92% over the next 12 months.

Following are ETFs with the highest allocation to Biohaven Pharmaceutical Holding Co Ltd's stock :

IBRN

As per our most recent records Biohaven Pharmaceutical Holding Co Ltd has 239 Employees.

Biohaven Pharmaceutical Holding Co Ltd's registered address is 215 Church Street, New Haven, CT, United States, 06510. You can get more information about it from Biohaven Pharmaceutical Holding Co Ltd's website at https://www.biohaven.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...